HER-2过表达型乳腺癌的分子生物学基础及治疗进展  

Molecular biology foundation and treatment progress on HER-2-overexpressing breast cancer

作　　者：姚孜琪[1] 姜达[1] 

机构地区：[1]河北医科大学第四医院肿瘤内科,河北石家庄050011

出　　处：《现代肿瘤医学》2013年第6期1407-1410,共4页Journal of Modern Oncology

摘　　要：乳腺癌是一类受激素受体调控且高度异质性的恶性肿瘤,不同类型乳腺癌无病生存期、复发转移率及预后均不相同。其中HER-2过表达型乳腺癌恶性程度高、生存率低,预后相对较差。但却是曲妥珠单抗进行分子靶向治疗的较好的适应症,可极大的改善该类患者的生存率。但由于药物耐药性、靶向效率低等,乳腺癌的最终复发不可避免。针对曲妥珠单抗耐药以后的后续治疗成为新的研究热点,本文介绍了HER-2过表达型乳腺癌发生的分子生物学基础及相应的信号传导过程,及以此为基础开发了一系列新药。Breast cancer is a a kind of highly heterogeneous malignant tumor by hormone receptor regulation.Different molecular subtypes of disease-free survival,recurrence rate and prognosis are not the same.Patients with HER-2-overexpressing breast cancer diagnosis often experience A higher malignant degree,low survival rate and inferior prognosis,The humanized monoclonal antibody trastuzumab is currently the foundation of treatment for HER-2-overexpressing breast cancer.However,due to drug resistance,targeting low efficiency,breast cancer eventually relapse inevitable.The follow-up treatment after trastuzumab resistant become a new hotspot.This article describes the basis of the molecular biology of HER-2-overexpressing breast cancer and corresponding signal transduction pathways,and as a basis for the development of a series of new drugs.

关 键 词：乳腺癌 HER-2过表达 分子生物学 曲妥珠单抗 

分 类 号：R737.9[医药卫生—肿瘤]